Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial

12Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Growth hormone releasing peptides (GHRPs) are synthetic peptides with the ability to stimulate human growth hormone (hGH) secretion. Several GHRPs have been developed as drug candidates; however, only one of them, GHRP-2 (Pralmorelin), has received a clinical approval. Nevertheless, they are distributed on the black market and misused by cheating athletes, due to their performance-enhancing effects. Hence, GHRPs have been included in the World-Anti-Doping-Agency's Prohibited List as forbidden substances in sport. Predominantly, analytical methods for detection and unequivocal identification of doping substances are based on mass spectrometry. Therefore, in the present work, a qualitative analysis by liquid chromatography coupled to high-resolution tandem mass spectrometry with a quadrupole time-of-flight analyzer was performed to identify a new heptapeptide (MW = 874.02 Da) – a glycine analogue of GHRP-2. Structure determination using de novo sequencing is described here in detail. The results of this study may indicate a new approach to circumvent a detection of doping practices.

Cite

CITATION STYLE

APA

Popławska, M., & Błażewicz, A. (2019). Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial. Drug Testing and Analysis, 11(1), 162–167. https://doi.org/10.1002/dta.2467

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free